Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

by Marie Robin, Liesbeth C. de Wreede, Christine Wolschke, Johannes Schetelig, Dirk-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Aleksandar Radujkovic, Donal McLornan, Yves Chalandon, and Nicolaus Kröger

Haematologica 2019 [Epub ahead of print]

Citation: Marie Robin, Liesbeth C. de Wreede, Christine Wolschke, Johannes Schetelig, Dirk-Jan Eikema, Maria Teresa Van Lint, Nina Simone Knelange, Dietrich Beelen, Arne Brecht, Dietger Niederwieser, Antonin Vitek, Wolfgang Bethge, Renate Arnold, Jürgen Finke, Liisa Volin, Ibrahim Yakoub-Agha, Arnon Nagler, Xavier Poiré, Hermann Einsele, Patrice Chevallier, Ernst Holler, Per Ljungman, Stephen Robinson, Aleksandar Radujkovic, Donal McLornan, Yves Chalandon, and Nicolaus Kröger. Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis.
Haematologica. 2019; 104:xxx
doi:10.3324/haematol.2018.205211

Publisher's Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

Marie Robin1, Liesbeth C. de Wreede2, Christine Wolschke3, Johannes Schetelig4, Diederik-Jan Eikema5, Maria Teresa Van Lint6, Nina Simone Knelange7, Dietrich Beelen8, Arne Brecht9, Dietger Niederwieser10, Antonin Vitek11, Wolfgang Bethge12, Renate Arnold13, Jürgen Finke14, Lisa Volin15, Ibrahim Yakoub-Agha16, Arnon Nagler17, Xavier Poiré18, Hermann Einsele19, Patrice Chevallier20, Ernst Holler21, Per Ljungman22, Stephen Robinson23, Alekxandar Radujkovic24, Donal McLornan25, Yves Chalandon26 and Nicolas Kröger2

1 Hôpital Saint-Louis, APHP, Université Paris 7, Paris, France
2 Dept. of Biomedical Data Sciences, JUMC, Leiden, The Netherlands & DKMS CTU, Dresden, Germany
3 University Hospital Eppendorf, Hamburg, Germany
4 Medizinische Klinik und Poliklinik I, Universitätshospital Dresden
5 EBMT Statistical Unit, Leiden, The Netherlands
6 Ospedale San Martino, Genova, Italy
7 EBMT Data office, Leiden, The Netherlands
8 University Hospital, Essen, Germany
9 Helios HSK Wiesbaden, Wiesbaden, Germany
10 University Hospital Leipzig, Leipzig, Germany
11 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
12 Universität Tübingen, Tübingen, Germany
13 Charité Universitätsmedizin Berlin, Berlin, Germany
14 Division of medicine I, hematology, Oncology and stem cell transplantation, University of Freiburg, Freiburg, Germany
15 HUCH Comprehensive Cancer Center, Helsinki, Finland
16 CHU de Lille, INSERM U995, Lille, France
17 Chaim Sheba Medical Center, Tel-HaShomer, Israel
18 Cliniques Universitaires St. Luc, Brussels, Belgium
19 Department of Internal Medicine II, University hospital Würzburg, Würzburg, Germany
20 CHU Nantes, Nantes, France
21 University Regensburg, Regensburg, Germany
22 Karolinska University Hospital, Stockholm, Sweden
23 Bristol Oncology Centre, Bristol, UK
24 University of Heidelberg, Heidelberg, Germany
25 Comprehensive Cancer Centre, Department of Haematology, Kings College, London, UK
26 Hôpitaux Universitaires de Genève and Faculty of Medicine, University of Geneva, Geneva, Switzerland

Corresponding author: Marie Robin
Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris
Tel : 0033142494949 Fax : 0142499636
marie.robin@aphp.fr

Running title: long-term outcome after transplant in MF patients
ABSTRACT

Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first 2 years and hence we aimed to analyze the outcome of 2-year disease-free survivors. 1055 patients with myelofibrosis transplanted between 1995 and 2014 and registered in the registry of the European Society for Blood and Marrow Transplantation were included. Survival was compared to the matched general population to determine excess mortality and the risk factors that are associated. In the 2-year survivors, Disease-free survival was 64% (60-68%) and Overall Survival was 74% (71-78%) at 10 years, better in younger individuals and in women. Excess mortality was 14% (8-21%) in patients < 45 years and 33% (13-53%) in patients ≥ 65 years. The main cause of death was relapse of the primary disease. Graft versus Host Disease before 2 years decreased the risk of relapse. Multivariable analysis of excess mortality showed that age, male sex recipient, secondary myelofibrosis and no Graft Versus Host disease prior to the 2-year landmark increased the risk of excess mortality.

This is the largest study to date analyzing long-term outcome in patients with myelofibrosis undergoing transplant. Overall it shows a good survival in patients alive and in remission at 2-years but the occurrence of late complications, including late relapses, infectious complications and secondary malignancies highlights the importance of screening and monitoring of long-term survivors.

Key words: allogeneic hematopoietic stem cell transplantation, myelofibrosis, long-term follow-up
INTRODUCTION

Myelofibrosis (MF) is a malignant clonal disease which can be classified as either primary or secondary to either essential thrombocythemia (ET) or polycythemia Vera (PV). The clinical phenotype of MF is markedly heterogeneous and disease severity can be assessed by a number of different prognostic scoring systems. For example, utilizing Dynamic International Prognostic Scoring System “DIPSS-PLUS”, low, int-1, int-2 and high-risk patients have a median survival of 15 years, 6.5 years, 35 months and 16 months, respectively. JAK-2 inhibitors, specifically ruxolitinib which remains the only licensed therapeutic agent in MF, alleviate many symptoms and even possibly increase survival, are not considered curative. Only allogeneic hematopoietic stem cells transplant (HSCT) has been proposed as curative, overall, HSCT has been reported to cure between 30 to 65% of these patients. One registry paper analyzed the timing to transplant in patients aged <65 years and concluded that those with intermediate-2 or high-risk disease are those who clearly benefit from transplantation strategies. This analysis included transplant-episodes prior to the ruxolitinib era and the role of this agent on transplantation strategies remains under debate. Early mortality (within 2 years) after transplantation is known to be between 10 and 30% but to date, there is no study which has analyzed the outcome of MF transplanted patients after this early period. In contrast, long-term outcome studies have been published for HSCT recipients who have more common disease types such as acute leukemia, lymphoma and chronic myeloid leukemia. Understanding the long-term outcome for transplanted MF patients will facilitate enhanced monitoring and an increased awareness of the potential risks of relapse or indeed mortality, specifically when compared to the general population.
METHODS

Patient selection

Only patients from countries of which the population mortality tables are available in a uniform format through the Human Mortality Database allowing a sex and age matched comparison, and contributing more than twenty allogeneic transplantations for MF were included in the study. Patients younger than 18 years and those who were transplanted from an unrelated matched cord blood were excluded. Patients were analyzed at the time of their first allogeneic transplant only. 2459 patients received a first allogeneic HCT between January 1995 and December 2014 for primary or secondary MF. A total of 1055 out of these 2459 patients were reported alive and free of their disease at 2-years after HSCT, these patients were considered for the study and called long-term (disease-free) survivors. These patients were transplanted in 178 centers in 15 countries.

Definitions

Relapse was defined as disease recurrence. Causes of death were classified as related to relapse if the patient experienced a relapse at any period during follow-up. Excess mortality was defined as the difference between mortality observed in the myelofibrosis landmark cohort and mortality in a matched cohort of the general population.

Statistical analysis

The endpoints of interest were overall survival (OS), disease-free survival (DFS), relapse/progression and non-relapse mortality (NRM) within the first 10 years after HSCT for patients alive and disease-free at the two-year landmark (LM) after HSCT. For all outcomes, patients were considered to be at risk since this LM. Median follow-up was determined using the reverse Kaplan-Meier method. OS was defined as the time since landmark until death from any cause, with surviving patients censored at the time of last follow-up. Patients still at risk at 10 years after HSCT were administratively censored. DFS was defined as time to death or relapse/progression ( whichever occurred first). OS and DFS were estimated using the Kaplan-Meier product limit estimation method, and differences in subgroups were assessed by the Log-Rank test. The cumulative incidences of relapse/progression (CIR) and non-relapse mortality (NRM) were analyzed together in a competing risks framework. Competing risks analyses were also applied to estimate the incidences of (extensive) chronic GVHD (cGVHD) and secondary malignancies, each with the competing event death, at 10 years after HSCT. Previous
acute GVHD (aGVHD) in the landmark population was quantified as a simple proportion, since all cases of aGVHD occurred prior to the 2-year landmark time point. Cox proportional hazards regression was used to assess the impact of potential risk factors on OS, RFS, CIR and NRM. CIR and NRM were analysed in a competing risks framework in which the cause specific hazards (CSH) were modelled.

Methods from relative survival were used to estimate the proportion of the deaths observed in our cohort which could be attributed to population causes (population mortality) and which to MF-related causes, including HSCT and pre-treatment (excess mortality)26,27. Patients were matched by age, sex and country and year of HSCT to a cohort from the general population, for whom survival information was available in the population tables in the Human Mortality Database (http://www.mortality.org). In univariable and multivariable analyses, the excess hazard of death was defined as the difference between the observed hazard in the patient cohort (this myelofibrosis cohort) and the hazard of the matched general population cohort. For multivariable analyses, we estimated Cox proportional hazards models for the excess hazard of death. Risk factors considered were age, sex, MF classification (primary versus secondary), conditioning intensity, Total Body Irradiation (TBI), donor type, stem cell source and previous GVHD (defined as the development of any type of GvHD between transplantation and the 2-year landmark). All estimates are reported with 95% confidence intervals. All analyses were performed in SPSS version 23 and R 3.3.0 (https://cran.r-project.org/), packages ‘survival’, ‘cmprsk’, ‘prodlim’ and ‘relnsur’.
RESULTS

Characteristics of patients and transplant

Characteristics of the entire patient cohort and the long-term survivors are shown in Table 1. Long-term survivors were transplanted at a median age of 53.5 years, 837 (79%) patients had primary MF at the time of transplantation, 645 (63%) patients received a reduced intensity regimen and 471 (45%) were transplanted using an HLA-matched sibling donor.

Outcome and predictors for outcome

In the entire cohort including 2459 patients (without landmark), OS and DFS at 10 years were 41% (95%CI: 39-44) and 32% (95%CI: 30-35). Median follow-up in the landmark population was 49.7 months (95%CI: 47-52). In the 1055 long-term survivors, 166 deaths were registered within 10 years after HSCT. For all time periods, the most common cause of death was relapse of MF, followed by GVHD and infection, with a higher occurrence of infection-related deaths between 2- and 5-years post-transplant (Table 2). In the LM population, secondary cancers occurred in 34 patients before the landmark and in 87 patients after the landmark. This translated into a cumulative incidence in the LM population without cancer before the LM at 10 years of 14% (11-18) 10 years after the transplantation. The most frequent cancer was solid tumor (70% of whom 3 breast cancers), followed by acute leukemia or myelodysplastic syndrome (17%) and lymphoma (9%).

Grade 2-4 acute GVHD had occurred in 23% of the LM patients (n=245). Before landmark, 56% (576 patients) of the patients in the LM population had chronic GVHD of whom 263 patients had an extensive chronic GVHD. Among patients without chronic GVHD before the 2-year landmark, cumulative incidence of chronic extensive and limited GVHD were 13% (8-18) and 9% (5-12%), respectively. 10-year –OS and -DFS for 2-year survivors were 74% (71-78%) and 64% (60-68%) respectively (Figure 1). In these patients, relapse incidence and non-relapse mortality 10-years after transplant were estimated at 21% (17-24%) and 15% (12-18%) (Figure 1). Risk factors for mortality, DFS and relapse are shown in Table 3. Older age (p<0.001), type of myelofibrosis (higher risk for secondary myelofibrosis, p=0.01), male sex (p=0.004) and no GVHD before landmark (p=0.02) were associated with a significantly higher risk of mortality. Older age (p=0.033), RIC (p=0.017), male sex (p=0.003), donor other than an HLA-matched related donor (p=0.01) and no GVHD before landmark were associated significantly with lower DFS. Use of a donor other than HLA-matched related donor (p=0.008), RIC (p=0.042) and no GVHD occurrence before the landmark (p<0.001) significantly increased the risk for relapse.
Comparison to general population

The excess mortality of the two-year landmark MF cohort was 21% (18-25%) at 10-years whereas its population mortality was 4% (4-4.2%) (Figure 2). Excess mortality was lower in younger patients and in female gender recipients but remained considerably greater than the matched population mortality (Figure 2). Excess mortality in the younger cohort (< 45 years) was 14% (8-21%) and population mortality was 1% (1-1.1%) at this age. In contrast, excess mortality in the older cohort (≥65 years) was 33% (13-53%) and population mortality was 12% (10-14%).

Risk factors for late excess mortality

A Cox model was developed to estimate the risk factors for excess mortality in the 2-year disease-free survivors. Of note, the interpretation of the influence of variables in this landmark model applies to patients alive and free of the disease 2-years following transplantation. For instance, patients with severe GVHD may not survive the second year post-transplant but the subset of patients who survived with such GVHD are incorporated in the model. The multivariable model shows that older age, MF secondary to PV or ET, male gender recipient were risk factors for excess mortality (Table 4). In long-term survival, previous GVHD was protective for mortality (Table 4). The model highlights that age and sex, which were at higher risk in the general model, are still risk factors for excess mortality. Figure 3 shows changes in the hazard of excess mortality of for reference patients according to Cox model (variables from the Table 4) transplanted at the age of 50 years, the hazards are given for men and for women separately. We can see that there is a decline in hazard of excess mortality over time post HSCT but after 3 years (5 years post-transplant), there is a kind of plateau.
DISCUSSION

This EBMT report of 1055 patients alive and in remission at 2-years after HSCT is the largest study of long-term post-transplant outcome in patients with MF. Results indicate that survival 10 years after transplantation in these 2-year survivors is 74% but also that the mortality rate does not decrease to that expected in the general population. This is the first long-term study in myelofibrosis with the method of landmark analysis. Previously, it has been reported in other diseases that long-term outcome in transplanted patients remains lower than expected in general population (except in aplastic anemia)\(^\text{20, 21}\). Our results can be considered disappointing as compared to previous publications, especially from CIBMTR, but the median age was 2 decades higher in our cohort which could explain the higher long-term mortality. Indeed, we could confirm that in a subgroup of patients younger than 45 years, OS was very good OS at 86% 10-years after transplantation. Two additional recent long-term analyses in patients with chronic malignancies (chronic lymphocytic leukemia (CLL) and myelodysplastic syndrome (MDS)) from EBMT registry included patients with a median age closer to MF patients, estimated long-term survival lower than in this MF cohort\(^\text{27,24}\). Similar risk factors for mortality were found with a better OS in women and in younger\(^\text{24}\) patients. The higher risk in male recipients is not totally elucidated but usually it is thought to be possibly due to higher risk behavior and also to higher propensity towards comorbidities such as cardio-vascular disease\(^\text{28}\). In contrast, an EBMT study led in patients with acute myeloid leukemia did not show age and sex were predictors for OS\(^\text{29}\).

Akin to other malignant disorders, late relapse was the leading cause of death in MF patients following HSCT\(^\text{19-22,24,29}\). Relapse incidence at 10-years after transplant in the long-term survivors is 21%, concordant with that expected in other malignant disorders and highlights that even if the relapse risk decreases over time, it can still occur late after transplant. Many studies have reported that relapse risk is related to the disease risk at the time of transplant. Unfortunately, due to the retrospective registry-based nature of this study, we did not have sufficient data to calculate a relevant IPSS and so unfortunately could not analyze this aspect. However, we observed that the relapse risk was higher in patients who received a RIC, which could be expected but were surprised that in long-term survivors, the intensity of the regimen still had some impact. In acute myeloid leukemia, the EBMT long-term study, did not find that regimen intensity still has influence on late relapse\(^\text{29}\). Occurrence of acute or chronic GVHD before the landmark was the strongest factor preventing relapse in long-term survivors\(^\text{17,18,17,18,17,18}\). While in many other studies, GVHD increased the risk of late deaths, we failed to confirm this assertion in our MF cohort\(^\text{19,20}\). GVHD before landmark (2 years) in long-term survivors was protective for both relapse risk as well as for mortality. Of course, from this analysis, we cannot extrapolate that GVHD is needed to improve long-
term outcome, because patients with GVHD leading to death in the first 2 years of transplant have been excluded from the study, per se.

The weakness for GVHD analysis within this cohort was that we could not delineate the risk of “active GVHD” because we had no data regarding GVHD resolution, albeit that it is probable that patients still alive at 2 years with chronic GVHD were those with the less severe GVHD. The vast majority of patients had onset of chronic GVHD before the landmark but some patients had also a late onset. Finally, the majority of survivors suffered (or had suffered) from chronic GVHD which may alter their quality of life and it is noteworthy that even if they are in remission from their myelofibrosis, patients could have a chronic GVHD which can be a cause of death especially before 5 years.

Infectious complications remained a frequent cause of death between 2 and 5 years post-transplant. It has been previously reported that splenectomy before transplant increased the risk of late severe infection which may in part contribute to these findings within the MF-cohort. This high risk of lethal infection should be taken into account in long-term monitoring strategies and highlights the importance of appropriate anti-infective prophylaxis.

Second malignancies were also the cause of very late deaths, justifying long-term monitoring and cancer prevention in this population. After 5-years, 16% of deaths were due to second malignancies and at 10 years, cumulative incidence of secondary cancer was 14%. We could not analyze specific risk factors for second malignancies due to the small numbers involved. There are few long-term survivors for non-transplanted higher risk MF so there is no data for long-term secondary cancers within that population is unknown. It is hard to determine how the transplantation process increases the risk of cancer but chemotherapy, radiotherapy, immune deficiency, chronic GVHD, genetic susceptibility as well as age can cumulatively contribute towards an increased susceptibility.

To conclude, patients with MF have good survival when alive and in remission 2-years after transplantation, especially younger and female recipients. Severe late complications and late relapses should be monitored and prevention highlighted in order to reduce life threatening complications. Lifelong follow-up is required to optimize long-term outcomes.
Author Conflict of Interest Statement: DML: Novartis speaker, Jazz Pharmaceutical advisory board. YC: Novartis advisory board and travel grant. NK: research grant and Honoria from Neovii. JF: research grant, speaker Honoria and travel support with MEDAC, NEOVII, NOVARTIS, RIEMSER;

Author contributions: MR, YC and NK designed the study, LDW and DJE did statistics, NSK did data management, MR, YC, NK, DML analyzed the data, MR, CW, JS, MTVL, DB, AB, DN, AV, WB, RA, JF, LV, IYA, AN, XP, HE, PC, EH, PL, ST, AR and NK provided the patients, MR wrote the paper, all co-authors had opportunity to discuss results and approved the final manuscript.
References

1. Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J Clin Oncol. 2011;29(4):392–397.

2. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.

3. Verstovsek S, Mesa RA, Gotlib J, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica. 2013;98(12):1865–1871.

4. Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017;10(1):55.

5. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood. 1999;93(9):2831–2838.

6. Kerbauy DMB, Gooley TA, Sale GE, et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocytopenia. Biol Blood Marrow Transplant. 2007;13(3):355–365.

7. Patriarca F, Bacigalupo A, Sperotto A, et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica. 2008;93(10):1514–1522.

8. Kröger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264–5270.

9. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2010;16(3):358–367.

10. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). Br J Haematol. 2011;152(3):331–339.

11. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014;20(1):89–97.

12. Rondelli D, Goldberg JD, Isola L, et al. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014;124(7):1183–1191.

13. Ditschkowski M, Elmaagaci AH, Trenschel R, et al. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica. 2012;97(10):1574–1581.
14. Deeg HJ, Gooley TA, Flowers MED, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood. 2003;102(12):3912–3918.

15. Scott BL, Gooley TA, Sorror ML, et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood. 2012;119(11):2657–2664.

16. Samuelson Bannow BT, Salit RB, Storer BE, et al. Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. Biol Blood Marrow Transplant. 2018;24(2):386–392.

17. Kröger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015;125(21):3347–3350; quiz 3364.

18. Cervantes F, Pereira A. Does ruxolitinib prolong the survival of patients with myelofibrosis? Blood. 2017;129(7):832–837.

19. Socié G, Stone JV, Wingard JR, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med. 1999;341(1):14–21.

20. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230–2239.

21. Goldman JM, Majhail NS, Klein JP, et al. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010;28(11):1888–1895.

22. Martin PJ, Counts GW, Appelbaum FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28(6):1011–1016.

23. Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110(10):3784–3792.

24. van Gelder M, de Wree de LC, Bornhäuser M, et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52(3):372–380.

25. Iacobelli S, EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48 Suppl 1S1–37.

26. Pohar Perme M, Estève J, Rachet B. Analysing population-based cancer survival - settling the controversies. BMC Cancer. 2016;16(1):933.

27. Schetelig J, de Wree de LC, van Gelder M. Late Treatment-related Mortality versus Competing Causes of Death after Allogeneic Transplantation for Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia. Leuk Press. 2018 Dec 20. [Epub ahead of print]
28. Pophali PA, Klotz JK, Ito S, et al. Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. Exp Hematol. 2014;42(2):83–89.

29. Shimoni A, Labopin M, Savani B, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. 2016;9(1):118.

30. Robin M, Porcher R, De Castro Araujo R, et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biol Blood Marrow Transplant. 2007;13(11):1304–1312.

31. Syrjala KL, Martin PJ, Lee Sj. Delivering care to long-term adult survivors of hematopoietic cell transplantation. J Clin Oncol. 2012;30(30):3746–3751.

32. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Rev Bras Hematol Hemoter. 2012;34(2):109–133.

33. Bhatia S, Armenian SH, Landier W. How I monitor long-term and late effects after blood or marrow transplantation. Blood. 2017;130(11):1302–1314.
| Table 1. Patients and transplant characteristics |
|-----------------------------------------------|
|                                                |
| **Whole cohort**                              | **2-year land mark** |
| Numbers | % | Numbers | % |
|---------|---|---------|---|
| **Total number of patients**                  | 2459 | 1055  |
| **Disease at time of transplant**             |       |
| Primary myelofibrosis                         | 1904  | 78   |
| Secondary myelofibrosis                       | 421   | 17   |
| Transformation into acute leukemia            | 134   | 5    |
| **Median age at HSCT, years**                 | 55    | 53.5 |
| Age < 45 years                                | 355   | 14   |
| Age 45-54 years                               | 729   | 30   |
| Age 55-64 years                               | 1137  | 46   |
| Age >= 65 years                               | 238   | 10   |
| **Interval primary diagnosis and transplant** |       |
| Median                                         |       |
| < 12 months                                    | 743   | 30   |
| >=12 months                                    | 1716  | 70   |
| **Conditioning regimen**                      |       |
| Reduced intensity                              | 1502  | 63   |
| Standard                                       | 877   | 37   |
| Total body irradiation Yes                     | 423   | 17   |
| No                                             | 2015  | 83   |
| **Source of stem cells**                      |       |
| Marrow                                         | 332   | 14   |
| Blood                                          | 2127  | 86   |
| HLA matched sibling donor                      | 1022  | 43   |
| Other                                          | 1379  | 57   |
| **Unreported data found for regimen and type of donor but always < 4%** |


Table 2. Causes of mortality after 2 years

| Years from transplant       | 2 - 5y N | 2 - 5y % | >5 - 10y N | >5 - 10y % |
|-----------------------------|----------|----------|------------|-----------|
| Relapse/progression         | 33       | 41       | 30         | 61        |
| Secondary malignancy*       | 9        | 11       | 8          | 16        |
| GvHD                        | 18       | 22       | 9          | 19        |
| Infection                   | 17       | 21       | 2          | 4         |
| Organ damage/toxicity       | 4        | 5        |            |           |
| Unknown                     | 28       | 8        |            |           |
| Total                       | 109      | 57       |            |           |

* including post-transplant lymphoproliferative disease
Table 3. Multivariable (cause-specific) Cox proportional hazards models for outcomes in the period between 2 and 10 years after HSCT for patients alive and disease-free at 2 years after HSCT

| Variables                      | Overall survival | P-value | Disease-free survival | P-value | Relapse | P-value |
|--------------------------------|------------------|---------|-----------------------|---------|---------|---------|
|                                | HR (95%CI)       |         | HR (95%CI)            |         | HR (95%CI) |         |
| Age (per decade)               | 1.45 (1.19 - 1.76) | <0.001  | 1.18 (1.01 - 1.37)    | 0.033   | 1.16 (0.96 - 1.42) | 0.131   |
| Patient sex                    |                  |         |                       |         |         |         |
| Male                           | 1                |         | 1                     |         | 1       |         |
| Female                         | 0.58 (0.4 - 0.84) | 0.004   | 0.65 (0.49 - 0.87)    | 0.003   | 0.79 (0.55 - 1.14) | 0.205   |
| MF classification              |                  |         |                       |         |         |         |
| PMF                            | 1                |         | 1                     |         | 1       |         |
| SMF                            | 1.66 (1.13 - 2.44)| 0.01    | 1.35 (0.97 - 1.88)    | 0.071   | 1.07 (0.67 - 1.7) | 0.78    |
| Source of stem cells           |                  |         |                       |         |         |         |
| Marrow                         | 1                |         | 1                     |         | 1       |         |
| PB                             | 0.83 (0.51 - 1.34)| 0.442   | 0.77 (0.52 - 1.13)    | 0.178   | 0.67 (0.41 - 1.09) | 0.107   |
| Cond. reg. intensity           |                  |         |                       |         |         |         |
| MAC                            | 1                |         | 1                     |         | 1       |         |
| RIC                            | 1.17 (0.79 - 1.73)| 0.434   | 1.48 (1.07 - 2.04)    | 0.017   | 1.54 (1.02 - 2.35) | 0.042   |
| Cond. reg. with Chemo only     |                  |         |                       |         |         |         |
| TBI                            | 1                |         | 1                     |         | 1       |         |
|                                | 1.25 (0.81 - 1.93)| 0.322   | 1.28 (0.89 - 1.82)    | 0.18    | 1.28 (0.8 - 2.06) | 0.305   |
| Type of donor                  |                  |         |                       |         |         |         |
| Matched sibling                | 1                |         | 1                     |         | 1       |         |
| Unrelated                      | 1.08 (0.77 - 1.51)| 0.669   | 1.48 (1.09 - 1.89)    | 0.011   | 1.65 (1.14 - 2.39) | 0.008   |
| Any previous GVHD              | 0.67 (0.48 - 0.94)| 0.02    | 0.62 (0.47 - 0.81)    | 0.001   | 0.42 (0.3 - 0.6) | <0.001   |
**Table 4.** A multivariable Cox proportional hazards model for excess mortality in the period between 2 and 10 years after HSCT for patients alive and disease-free at 2 years after HSCT

|                          | Hazard ratio | 95% confidence interval | P-value |
|--------------------------|--------------|--------------------------|---------|
| **Patient sex**          |              |                          |         |
| Male                     | 1            | 0.62                     | 0.41 - 0.93 | 0.022 |
| Female                   | 1            | 0.62                     | 0.41 - 0.93 | 0.022 |
| **Age (per decades)**    | 1.35         |                          | 1.08 - 1.69 | 0.008 |
| **Disease**              |              |                          |         |
| Primary myelofibrosis    | 1            | 1.81                     | 1.18 - 2.78 | 0.007 |
| Secondary myelofibrosis  | 1            | 1.81                     | 1.18 - 2.78 | 0.007 |
| **Standard**             | 1            |                          |         |
| Reduced intensity regimen| 1.16         |                          | 0.74 - 1.82 | 0.527 |
| No TBI                   | 1            |                          |         |
| TBI in regimen           | 1.25         |                          | 0.75 - 2.08 | 0.384 |
| **Donor**                |              |                          |         |
| Matched sibling donor    | 1            |                          |         |
| Other donor              | 1.1          |                          | 0.75 - 1.63 | 0.623 |
| **Source of stem cells** |              |                          |         |
| Marrow                   | 1            |                          |         |
| Blood                    | 0.83         |                          | 0.48 - 1.44 | 0.515 |
| **GVHD**                 |              |                          |         |
| No                       | 1            |                          |         |
| Any                      | 0.65         |                          | 0.44 - 0.96 | 0.031 |
Legends to Figures

Figure 1. Outcome of myelofibrosis patient from landmark time

Left panel: overall Survival and Disease Free Survival from landmark time. Solid line is OS, dashed line is DFS. Right panel: relapse incidence and non-relapse mortality. Solid line is relapse, dashed line is non-relapse mortality.

Figure 2. Mortality in myelofibrosis compared to general population

Top figure: The plots show mortality of the disease-free survivors (black line) and in general population (grey line) mortality. Middle figure: The plots show mortality of the myelofibrosis patients according to sex (black solid line in female and dashed line in male) and the mortality in the general population (grey lines). Down figure: the plots show mortality of disease-free survivors (black lines) and general population (grey lines) by age categories

Figure 3. Hazard rate for excess risk of mortality with post-transplant time

The curves show hazard rates for two reference patients, based on the Cox model for the excess hazard. They are both 50 years at HSCT, had primary MF, received standard conditioning, no TBI, a matched sibling donor, marrow as source of stem cells and no previous GVHD. The solid line shows a male patient and the dashed line a female patient.
